- Home
- ICON vs QLGN Comparison
ICON vs QLGN Comparison
Compare ICON & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- QLGN
- Stock Information
- Founded
- ICON 2023
- QLGN 1996
- Country
- ICON Greece
- QLGN United States
- Employees
- ICON N/A
- QLGN N/A
- Industry
- ICON
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- QLGN Health Care
- Exchange
- ICON Nasdaq
- QLGN Nasdaq
- Market Cap
- ICON 5.2M
- QLGN 4.7M
- IPO Year
- ICON 2024
- QLGN N/A
- Fundamental
- Price
- ICON $2.37
- QLGN $2.02
- Analyst Decision
- ICON Strong Buy
- QLGN
- Analyst Count
- ICON 1
- QLGN 0
- Target Price
- ICON $4.50
- QLGN N/A
- AVG Volume (30 Days)
- ICON 206.5K
- QLGN 2.6M
- Earning Date
- ICON 09-09-2025
- QLGN 08-13-2025
- Dividend Yield
- ICON 396.62%
- QLGN N/A
- EPS Growth
- ICON N/A
- QLGN N/A
- EPS
- ICON N/A
- QLGN N/A
- Revenue
- ICON $6,137,000.00
- QLGN N/A
- Revenue This Year
- ICON $51.78
- QLGN N/A
- Revenue Next Year
- ICON $51.90
- QLGN N/A
- P/E Ratio
- ICON N/A
- QLGN N/A
- Revenue Growth
- ICON 16.93
- QLGN N/A
- 52 Week Low
- ICON $1.60
- QLGN $2.00
- 52 Week High
- ICON $130.80
- QLGN $11.50
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- QLGN 23.58
- Support Level
- ICON N/A
- QLGN $2.00
- Resistance Level
- ICON N/A
- QLGN $2.98
- Average True Range (ATR)
- ICON 0.00
- QLGN 0.47
- MACD
- ICON 0.00
- QLGN -0.10
- Stochastic Oscillator
- ICON 0.00
- QLGN 1.30
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.